These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 19405118)

  • 1. Targeting AKT with the proapoptotic peptide, TAT-CTMP: a novel strategy for the treatment of human pancreatic adenocarcinoma.
    Simon PO; McDunn JE; Kashiwagi H; Chang K; Goedegebuure PS; Hotchkiss RS; Hawkins WG
    Int J Cancer; 2009 Aug; 125(4):942-51. PubMed ID: 19405118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells.
    Ng SSW ; Tsao MS; Chow S; Hedley DW
    Cancer Res; 2000 Oct; 60(19):5451-5. PubMed ID: 11034087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Silencing pancreatic adenocarcinoma upregulated factor (PAUF) increases the sensitivity of pancreatic cancer cells to gemcitabine.
    Gao CC; Xu XL; Li F; Gong BG; Liu S; Cui YQ; Sun HC; Xu PY; Zheng YM; Jiang H
    Tumour Biol; 2016 Jun; 37(6):7555-64. PubMed ID: 26684804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of AKT2 enhances sensitivity to gemcitabine via regulating PUMA and NF-κB signaling pathway in human pancreatic ductal adenocarcinoma.
    Chen D; Niu M; Jiao X; Zhang K; Liang J; Zhang D
    Int J Mol Sci; 2012; 13(1):1186-1208. PubMed ID: 22312312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HMGA1 is a molecular determinant of chemoresistance to gemcitabine in pancreatic adenocarcinoma.
    Liau SS; Whang E
    Clin Cancer Res; 2008 Mar; 14(5):1470-7. PubMed ID: 18316571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma.
    Ng SS; Tsao MS; Nicklee T; Hedley DW
    Mol Cancer Ther; 2002 Aug; 1(10):777-83. PubMed ID: 12492110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRG1 promotes chemoresistance of pancreatic cancer cells through crosstalking with Akt signalling.
    Liu X; Tian X; Wang F; Ma Y; Kornmann M; Yang Y
    Eur J Cancer; 2014 Sep; 50(13):2251-62. PubMed ID: 24953335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Wortmannin inhibits pkb/akt phosphorylation and promotes gemcitabine antitumor activity in orthotopic human pancreatic cancer xenografts in immunodeficient mice.
    Ng SS; Tsao MS; Nicklee T; Hedley DW
    Clin Cancer Res; 2001 Oct; 7(10):3269-75. PubMed ID: 11595724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FKBP5 as a selection biomarker for gemcitabine and Akt inhibitors in treatment of pancreatic cancer.
    Hou J; Wang L
    PLoS One; 2012; 7(5):e36252. PubMed ID: 22590527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RNA interference demonstrates a novel role for integrin-linked kinase as a determinant of pancreatic adenocarcinoma cell gemcitabine chemoresistance.
    Duxbury MS; Ito H; Benoit E; Waseem T; Ashley SW; Whang EE
    Clin Cancer Res; 2005 May; 11(9):3433-8. PubMed ID: 15867245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy in Pancreatic Cancer Models by Altering Ribonucleotide Reductase Subunit-1 (RRM1).
    Vena F; Li Causi E; Rodriguez-Justo M; Goodstal S; Hagemann T; Hartley JA; Hochhauser D
    Clin Cancer Res; 2015 Dec; 21(24):5563-77. PubMed ID: 26228206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LncRNA HIF1A-AS1 Promotes Gemcitabine Resistance of Pancreatic Cancer by Enhancing Glycolysis through Modulating the AKT/YB1/HIF1α Pathway.
    Xu F; Huang M; Chen Q; Niu Y; Hu Y; Hu P; Chen D; He C; Huang K; Zeng Z; Tang J; Wang F; Zhao Y; Wang C; Zhao G
    Cancer Res; 2021 Nov; 81(22):5678-5691. PubMed ID: 34593522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment with gemcitabine and TRA-8 anti-death receptor-5 mAb reduces pancreatic adenocarcinoma cell viability in vitro and growth in vivo.
    DeRosier LC; Huang ZQ; Sellers JC; Buchsbaum DJ; Vickers SM
    J Gastrointest Surg; 2006 Nov; 10(9):1291-300; discussion 1300. PubMed ID: 17114015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells.
    Duxbury MS; Ito H; Zinner MJ; Ashley SW; Whang EE
    Clin Cancer Res; 2004 Apr; 10(7):2307-18. PubMed ID: 15073106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pancreatic adenocarcinoma cell lines show variable susceptibility to TRAIL-mediated cell death.
    Ibrahim SM; Ringel J; Schmidt C; Ringel B; Müller P; Koczan D; Thiesen HJ; Löhr M
    Pancreas; 2001 Jul; 23(1):72-9. PubMed ID: 11451151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of Notch3 enhances sensitivity to gemcitabine in pancreatic cancer through an inactivation of PI3K/Akt-dependent pathway.
    Yao J; Qian C
    Med Oncol; 2010 Sep; 27(3):1017-22. PubMed ID: 19816816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. WNT5A modulates cell cycle progression and contributes to the chemoresistance in pancreatic cancer cells.
    Wei W; Sun HH; Li N; Li HY; Li X; Li Q; Shen XH
    Hepatobiliary Pancreat Dis Int; 2014 Oct; 13(5):529-38. PubMed ID: 25308364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer.
    Venkatasubbarao K; Peterson L; Zhao S; Hill P; Cao L; Zhou Q; Nawrocki ST; Freeman JW
    Mol Cancer; 2013 Sep; 12(1):104. PubMed ID: 24025152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic nicotine inhibits the therapeutic effects of gemcitabine on pancreatic cancer in vitro and in mouse xenografts.
    Banerjee J; Al-Wadei HA; Schuller HM
    Eur J Cancer; 2013 Mar; 49(5):1152-8. PubMed ID: 23146955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective disruption of rb-raf-1 kinase interaction inhibits pancreatic adenocarcinoma growth irrespective of gemcitabine sensitivity.
    Treviño JG; Verma M; Singh S; Pillai S; Zhang D; Pernazza D; Sebti SM; Lawrence NJ; Centeno BA; Chellappan SP
    Mol Cancer Ther; 2013 Dec; 12(12):2722-34. PubMed ID: 24107447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.